Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.4 CHF | -0.84% | -3.04% | -3.16% |
Feb. 16 | BB Biotech's Loss Narrows in FY23; Operating Income Down | MT |
Feb. 14 | BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | 101M 110M | Capitalization | 2.27B 2.49B |
---|---|---|---|---|---|
Net income 2024 * | 24M 26.34M | Net income 2025 * | 27M 29.64M | EV / Sales 2024 * | - |
Net Debt 2024 * | 291M 319M | Net Debt 2025 * | 324M 356M | EV / Sales 2025 * | 25.8 x |
P/E ratio 2024 * |
14.9
x | P/E ratio 2025 * |
13.9
x | Employees | 10 |
Yield 2024 * |
5.68% | Yield 2025 * |
5.8% | Free-Float | 97.24% |
1 day | -0.84% | ||
1 week | -3.04% | ||
Current month | -9.11% | ||
1 month | -11.73% | ||
3 months | -2.82% | ||
6 months | +8.52% | ||
Current year | -3.16% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Koller
CIO | Chief Investment Officer | 54 | 03-12-31 |
- | - | ||
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Clive Meanwell
BRD | Director/Board Member | 67 | 03-12-31 |
Director/Board Member | 63 | 19-12-31 | |
Chairman | 63 | 19-03-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 41.4 | -0.84% | 62,131 |
24-04-18 | 41.75 | -0.83% | 61,488 |
24-04-17 | 42.1 | -1.41% | 82,022 |
24-04-16 | 42.7 | -0.23% | 129,106 |
24-04-15 | 42.8 | +0.23% | 99,107 |
Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.16% | 2.5B | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- BION Stock